ASX - By Stock
|
NOX |
Re:
Ann: mRNA Vaccine Enhancer Shows Inflammation Reduction
|
|
stoicshrink
|
45 |
18K |
1 |
03/11/23 |
03/11/23 |
ASX - By Stock
|
45
|
18K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: mRNA Vaccine Enhancer Shows Inflammation Reduction
|
|
stoicshrink
|
45 |
18K |
2 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
45
|
18K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: mRNA Vaccine Enhancer Shows Inflammation Reduction
|
|
stoicshrink
|
45 |
18K |
0 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
45
|
18K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: US FDA grants Orphan Drug Designation for CRO-67
|
|
stoicshrink
|
64 |
28K |
2 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
64
|
28K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: US FDA grants Orphan Drug Designation for CRO-67
|
|
stoicshrink
|
64 |
28K |
1 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
64
|
28K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: US FDA grants Orphan Drug Designation for CRO-67
|
|
stoicshrink
|
64 |
28K |
3 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
64
|
28K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Pause in Trading
|
|
stoicshrink
|
7 |
2.8K |
1 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
7
|
2.8K
|
1
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Cholesterol-Lowering Program Update
|
|
stoicshrink
|
75 |
32K |
0 |
19/07/23 |
19/07/23 |
ASX - By Stock
|
75
|
32K
|
0
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Cholesterol-Lowering Program Update
|
|
stoicshrink
|
75 |
32K |
3 |
26/06/23 |
26/06/23 |
ASX - By Stock
|
75
|
32K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Details of Company Address
|
|
stoicshrink
|
11 |
5.3K |
6 |
19/06/23 |
19/06/23 |
ASX - By Stock
|
11
|
5.3K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Details of Company Address
|
|
stoicshrink
|
11 |
5.3K |
2 |
19/06/23 |
19/06/23 |
ASX - By Stock
|
11
|
5.3K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Details of Company Address
|
|
stoicshrink
|
11 |
5.3K |
1 |
19/06/23 |
19/06/23 |
ASX - By Stock
|
11
|
5.3K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: IONIC Trial Abstract Published at ASCO
|
|
stoicshrink
|
40 |
14K |
0 |
15/06/23 |
15/06/23 |
ASX - By Stock
|
40
|
14K
|
0
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Brain Injury Program Preclinical Development Update
|
|
stoicshrink
|
11 |
4.5K |
3 |
13/06/23 |
13/06/23 |
ASX - By Stock
|
11
|
4.5K
|
3
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Brain Injury Program Preclinical Development Update
|
|
stoicshrink
|
11 |
4.5K |
5 |
10/06/23 |
10/06/23 |
ASX - By Stock
|
11
|
4.5K
|
5
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Brain Injury Program Preclinical Development Update
|
|
stoicshrink
|
11 |
4.5K |
7 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
11
|
4.5K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
Ann: IONIC Trial Abstract Published at ASCO
|
|
stoicshrink
|
40 |
14K |
3 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
40
|
14K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: IONIC Trial Abstract Published at ASCO
|
|
stoicshrink
|
40 |
14K |
5 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
40
|
14K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: IONIC Trial Abstract Published at ASCO
|
|
stoicshrink
|
40 |
14K |
2 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
40
|
14K
|
2
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Cholesterol-Lowering Program Preclinical Studies Completed
|
|
stoicshrink
|
12 |
4.2K |
4 |
31/05/23 |
31/05/23 |
ASX - By Stock
|
12
|
4.2K
|
4
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Cholesterol-Lowering Program Preclinical Studies Completed
|
|
stoicshrink
|
12 |
4.2K |
4 |
30/05/23 |
30/05/23 |
ASX - By Stock
|
12
|
4.2K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: IONIC Trial Abstract Published at ASCO
|
|
stoicshrink
|
40 |
14K |
2 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
40
|
14K
|
2
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Cholesterol-Lowering Program Preclinical Studies Completed
|
|
stoicshrink
|
12 |
4.2K |
12 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
12
|
4.2K
|
12
|
|
ASX - By Stock
|
NOX |
Re:
Ann: IONIC Trial Abstract Published at ASCO
|
|
stoicshrink
|
40 |
14K |
4 |
26/05/23 |
26/05/23 |
ASX - By Stock
|
40
|
14K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Study results show new Sofra drug reduces inflammation
|
|
stoicshrink
|
8 |
3.6K |
3 |
22/05/23 |
22/05/23 |
ASX - By Stock
|
8
|
3.6K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Study results show new Sofra drug reduces inflammation
|
|
stoicshrink
|
8 |
3.6K |
4 |
19/05/23 |
19/05/23 |
ASX - By Stock
|
8
|
3.6K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Change of Director's Interest Notice - FB
|
|
stoicshrink
|
35 |
10K |
0 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
35
|
10K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Change of Director's Interest Notice - FB
|
|
stoicshrink
|
35 |
10K |
3 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
35
|
10K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: March 2023 Quarterly Activities Report and Appendix 4C
|
|
stoicshrink
|
26 |
8.6K |
3 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
26
|
8.6K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: March 2023 Quarterly Activities Report and Appendix 4C
|
|
stoicshrink
|
26 |
8.6K |
10 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
26
|
8.6K
|
10
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
|
|
stoicshrink
|
67 |
27K |
2 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
67
|
27K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
|
|
stoicshrink
|
67 |
27K |
1 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
67
|
27K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
|
|
stoicshrink
|
67 |
27K |
0 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
67
|
27K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
|
|
stoicshrink
|
67 |
27K |
2 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
67
|
27K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
|
|
stoicshrink
|
67 |
27K |
5 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
67
|
27K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Announces Novel mRNA Vaccine Enhancer
|
|
stoicshrink
|
32 |
9.1K |
7 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
32
|
9.1K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Announces Novel mRNA Vaccine Enhancer
|
|
stoicshrink
|
32 |
9.1K |
5 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
32
|
9.1K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Announces Novel mRNA Vaccine Enhancer
|
|
stoicshrink
|
32 |
9.1K |
2 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
32
|
9.1K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
IONIC may yet be a winner
|
|
stoicshrink
|
55 |
17K |
1 |
23/03/23 |
23/03/23 |
ASX - By Stock
|
55
|
17K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
IONIC may yet be a winner
|
|
stoicshrink
|
55 |
17K |
0 |
23/03/23 |
23/03/23 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
IONIC may yet be a winner
|
|
stoicshrink
|
55 |
17K |
0 |
23/03/23 |
23/03/23 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
IONIC may yet be a winner
|
|
stoicshrink
|
55 |
17K |
1 |
17/03/23 |
17/03/23 |
ASX - By Stock
|
55
|
17K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
IONIC may yet be a winner
|
|
stoicshrink
|
55 |
17K |
0 |
17/03/23 |
17/03/23 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
IONIC may yet be a winner
|
|
stoicshrink
|
55 |
17K |
0 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
IONIC may yet be a winner
|
|
stoicshrink
|
55 |
17K |
1 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
55
|
17K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
IONIC may yet be a winner
|
|
stoicshrink
|
55 |
17K |
0 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
55
|
17K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
IONIC may yet be a winner
|
|
stoicshrink
|
55 |
17K |
1 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
55
|
17K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Appendix 4D and Half Year 2023 Financial Report
|
|
stoicshrink
|
20 |
8.5K |
0 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
20
|
8.5K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Appendix 4D and Half Year 2023 Financial Report
|
|
stoicshrink
|
20 |
8.5K |
0 |
24/02/23 |
24/02/23 |
ASX - By Stock
|
20
|
8.5K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm to Present Sofra Study at LUPUS 2023 Conference
|
|
stoicshrink
|
4 |
2.3K |
13 |
22/02/23 |
22/02/23 |
ASX - By Stock
|
4
|
2.3K
|
13
|
|